Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JDHD | ISIN: IL0011417206 | Ticker-Symbol: 4SG
Frankfurt
20.11.24
08:00 Uhr
0,366 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SOL-GEL TECHNOLOGIES LTD Chart 1 Jahr
5-Tage-Chart
SOL-GEL TECHNOLOGIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,2780,59517:19

Aktuelle News zur SOL-GEL TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSol-Gel announces 180-day extension period for Nasdaq compliance2
MiSol-Gel Announces 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Requirement1
SOL-GEL TECHNOLOGIES Aktie jetzt für 0€ handeln
MiSol-Gel receives Nasdaq compliance extension2
FrSol-Gel Technologies GAAP EPS of -$0.01 beats by $0.04, revenue of $5.36M beats by $1.16M2
FrSol-Gel Technologies Ltd.: Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates82Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210...
► Artikel lesen
FrSol-Gel Technologies Ltd. - 6-K, Report of foreign issuer-
04.11.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
25.09.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer3
27.08.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
16.08.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
16.08.Sol-Gel Technologies Ltd.: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates175Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with...
► Artikel lesen
25.07.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
15.07.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
15.07.Sol-Gel Technologies CEO To Step Down; Eyal Ben-Or Appointed As CFO-
15.07.Sol-Gel Technologies announces CEO Seri-Levy to step down; promotes Eyal Ben-Or as CFO2
15.07.Sol-Gel Technologies Ltd.: Sol-Gel Technologies Announces Management Realignment2
28.05.Sol-Gel Technologies gets non-compliance notice from Nasdaq1
28.05.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1
20.05.Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates178Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China...
► Artikel lesen
16.05.Sol-Gel Technologies Ltd.: Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO in the Mainland of China, Hong Kong, Macau, Taiwan and Israel145NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1